XERIS BIOPHARMA HOLDINGS, INC. Interest Expense Nonoperating
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Interest Expense Nonoperating of $6.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $6.95M, a 5.59% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $6.88M, a 5.76% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $7.15M, a 7.14% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $7.27M, a 6.65% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense nonoperating for fiscal 2025 was $29.08M, a 4.60% decline from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense nonoperating for fiscal 2024 was $30.48M, a 14.57% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense nonoperating for fiscal 2023 was $26.61M, a 88.69% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense nonoperating for fiscal 2022 was $14.10M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.95M 10-Q · filed 2026-08-06 | $13.83M 10-Q · filed 2026-08-06 | $20.98M derived: sum of 3 quarters · filed 2026-08-06 | $28.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.88M 10-Q · filed 2026-05-07 | $14.04M derived: sum of 2 quarters · filed 2026-05-07 | $21.30M derived: sum of 3 quarters · filed 2026-05-07 | $28.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $14.42M derived: sum of 2 quarters · filed 2026-03-02 | $21.78M derived: sum of 3 quarters · filed 2026-08-06 | $29.08M 10-K · filed 2026-03-02 |
| 2025-09-30 | $7.27M 10-Q · filed 2025-11-06 | $14.63M derived: sum of 2 quarters · filed 2026-08-06 | $21.93M 10-Q · filed 2025-11-06 | $29.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $7.36M 10-Q · filed 2026-08-06 | $14.66M 10-Q · filed 2026-08-06 | $22.37M derived: sum of 3 quarters · filed 2026-08-06 | $30.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $7.30M 10-Q · filed 2026-05-07 | $15.01M derived: sum of 2 quarters · filed 2026-05-07 | $22.79M derived: sum of 3 quarters · filed 2026-05-07 | $30.76M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $15.49M derived: sum of 2 quarters · filed 2026-03-02 | $23.45M derived: sum of 3 quarters · filed 2026-03-02 | $30.48M 10-K · filed 2026-03-02 |
| 2024-09-30 | $7.79M 10-Q · filed 2025-11-06 | $15.75M derived: sum of 2 quarters · filed 2025-11-06 | $22.78M 10-Q · filed 2025-11-06 | $29.80M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $7.96M 10-Q · filed 2025-08-07 | $15.00M 10-Q · filed 2025-08-07 | $22.01M derived: sum of 3 quarters · filed 2026-03-02 | $28.86M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $7.03M 10-Q · filed 2025-05-08 | $14.05M derived: sum of 2 quarters · filed 2026-03-02 | $20.90M derived: sum of 3 quarters · filed 2026-03-02 | $27.43M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $7.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $13.87M derived: sum of 2 quarters · filed 2026-03-02 | $20.39M derived: sum of 3 quarters · filed 2026-03-02 | $26.61M 10-K · filed 2026-03-02 |
| 2023-09-30 | $6.85M 10-Q · filed 2024-11-08 | $13.38M derived: sum of 2 quarters · filed 2024-11-08 | $19.59M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $6.53M 10-Q · filed 2024-08-08 | $12.74M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $14.10M 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |